CND Life Sciences Opens Scottsdale Innovation Lab for Neurodiagnostic Assay Development

CND Life Sciences has opened a new innovation laboratory in Scottsdale, Arizona, with the stated goal of expanding its development of neurodiagnostic assays.

The company announced the facility as a dedicated space for assay development work — laboratory-built tests intended to support the evaluation of neurological disease. The announcement positions the Scottsdale lab as an operational expansion rather than a research collaboration: the site exists to increase the company's capacity to develop and refine its neurodiagnostic testing menu.

For clinical neurophysiology and neurology readers, the relevance is straightforward. Neurodiagnostic assays of the type CND develops sit alongside electrophysiological workups — scalp EEG, EMG, evoked potentials — as complementary tools in the diagnostic pathway for neurodegenerative and peripheral nerve disease. Where EEG and EMG characterize function, assay-based diagnostics aim to characterize underlying pathology. A commercial developer adding physical lab capacity signals intent to broaden that diagnostic menu.

What does the new lab actually change?

Based on the company's announcement, the Scottsdale innovation lab adds dedicated development space for neurodiagnostic assays. The facility's stated purpose is to expand assay development — that is, to increase the number and sophistication of tests CND can bring through development toward clinical availability.

The announcement does not specify:

• Which individual assay programs will move into the new facility first
• A timeline for new test launches
• Headcount or staffing figures for the Scottsdale site
• Any regulatory submissions tied to the expansion

Readers evaluating the practical impact for their own labs should treat the opening as an infrastructure investment: more development capacity, with specific pipeline outcomes to be confirmed as the company discloses them.

Why assay development capacity matters now

Demand for objective neurodiagnostic tools has grown as neurologists seek biological markers to support clinical impressions formed through electrophysiology and examination. Companies that develop such assays face a development bottleneck that is physical as much as scientific: assay validation, refinement, and scaling all require bench space, instrumentation, and staff.

By opening a dedicated innovation lab, CND Life Sciences addresses that bottleneck directly. The Scottsdale location consolidates development work in a facility the company controls, which typically shortens iteration cycles between assay design and validation compared with distributed or contracted arrangements.

What should clinicians watch next?

For monitoring units, reading rooms, and reference labs, the practical question is which assays emerge from the expanded development program and how they integrate with existing diagnostic workflows — including ordering pathways, sample handling, and interpretation alongside electrophysiological findings.

The announcement frames the Scottsdale lab as a growth step. The measure of its success will be concrete: new assays reaching clinicians, validated performance data published, and integration into the diagnostic workup for the neurological conditions CND targets. The company has not yet announced a date for the first output from the new facility.